Significance of HE4 Estimation in Comparison with CA125 in Diagnosis of Ovarian Cancer and Assessment of Treatment Response

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2013 Jan 25

PMID 23343214

Citations 39

Authors

Elham O Hamed

Hydi Ahmed

Osama B Sedeek

Abeer M Mohammed

Ali A Abd-Alla

Hazem M Abdel Ghaffar

Affiliations

Soon will be listed here.

Abstract

Background: Human epididymis protein 4 (HE4) is a novel and specific biomarker for ovarian cancer. The aim of this study is to evaluate a new tumor marker, HE4, in comparison with CA125 in diagnosis of epithelial ovarian cancer (EOC) and benign gynecological diseases.

Methods: CA125 and HE4 serum levels were determined in 30 patients with epithelial ovarian cancer (21 serous, 6 endometrioid and 3 mucinous tumors), 20 patients with benign gynecological diseases (8 patients with ovarian cyst, 5 patients with endometriosis, 4 patients with fibroid and 3 patients with pelvic inflammatory disease) and 20 healthy women. CA125 and HE4 cut-offs were 35 U/ml and 150 pmol/l, respectively.

Results: Serum HE4 and CA125 concentrations were significantly higher in the ovarian cancer patients compared with those seen in patients with benign disease or in the healthy controls (p = 0.001 and p < 0.001 respectively). In the receiver operating characteristic analysis (ROC), the area under the curve (AUC) values for HE4 was 0.96 (95% confidence interval, 0.9-1.0) and CA125 was 0.82 (95% confidence interval, 0.7-0.94). Compared to CA125, HE4 had higher sensitivity (90% vs. 83.3%), specificity (95% vs. 85%), PPV (93.1% vs. 80.7%) and NPV (92.7% vs. 87.2%), the combination of HE4 + CA125 the sensitivity and PPV reached 96.7% and 97% respectively.

Conclusion: Measuring serum HE4 concentrations along with CA125 concentrations may provide higher accuracy for detecting epithelial ovarian cancer.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1060413168685759.

Citing Articles

RNA modification regulators as promising biomarkers in gynecological cancers.

Qi Y, Li T, Zhou Y, Hao Y, Zhang J Cell Biol Toxicol. 2024; 40(1):92.

PMID: 39472384 PMC: 11522084. DOI: 10.1007/s10565-024-09924-y.

Molecular fingerprinting of biological nanoparticles with a label-free optofluidic platform.

Stollmann A, Garcia-Guirado J, Hong J, Ruedi P, Im H, Lee H Nat Commun. 2024; 15(1):4109.

PMID: 38750038 PMC: 11096335. DOI: 10.1038/s41467-024-48132-4.

High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Wilczynski J, Paradowska E, Wilczynski M Biomedicines. 2024; 12(1).

PMID: 38275400 PMC: 10813374. DOI: 10.3390/biomedicines12010229.

Molecular fingerprinting of biological nanoparticles with a label-free optofluidic platform.

Stollmann A, Garcia-Guirado J, Hong J, Im H, Lee H, Ortega Arroyo J Res Sq. 2023; .

PMID: 37886549 PMC: 10602063. DOI: 10.21203/rs.3.rs-3309306/v1.

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria.

Shittu K, Rabiu K, Akinola O, Ahmed S, Adewunmi A Ecancermedicalscience. 2023; 17:1568.

PMID: 37533954 PMC: 10393307. DOI: 10.3332/ecancer.2023.1568.

References

Park Y, Kim Y, Lee E, Lee J, Kim H . Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2011; 130(5):1136-44. DOI: 10.1002/ijc.26129. View

Rosen D, Wang L, Atkinson J, Yu Y, Lu K, Diamandis E . Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005; 99(2):267-77. DOI: 10.1016/j.ygyno.2005.06.040. View

Rustin G, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T . Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011; 21(2):419-23. DOI: 10.1097/IGC.0b013e3182070f17. View

Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R . A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2007; 18(3):414-20. DOI: 10.1111/j.1525-1438.2007.01035.x. View

Park Y, Lee J, Hong D, Lee E, Kim H . Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011; 44(10-11):884-8. DOI: 10.1016/j.clinbiochem.2011.04.011. View

Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N . No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011; 121(3):487-91. DOI: 10.1016/j.ygyno.2011.02.022. View

Paek J, Lee S, Yim G, Lee M, Kim Y, Nam E . Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2011; 158(2):338-42. DOI: 10.1016/j.ejogrb.2011.05.021. View

Molina R, Escudero J, Auge J, Filella X, Foj L, Torne A . HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011; 32(6):1087-95. PMC: 3195682. DOI: 10.1007/s13277-011-0204-3. View

Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H . Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009; 100(8):1315-9. PMC: 2676558. DOI: 10.1038/sj.bjc.6605011. View

10.

Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A . Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol. 2012; 7:124. PMC: 3523067. DOI: 10.1186/1746-1596-7-124. View

11.

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M . The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med. 2011; 49(3):521-5. DOI: 10.1515/CCLM.2011.075. View

12.

Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

13.

Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F . Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010; 28(13):2159-66. PMC: 2860434. DOI: 10.1200/JCO.2008.19.2484. View

14.

Asher V, Khan R, Warren A, Shaw R, Schalkwyk G, Bali A . The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010; 5:78. PMC: 3016344. DOI: 10.1186/1746-1596-5-78. View

15.

Havrilesky L, Darcy K, Hamdan H, Priore R, Leon J, Bell J . Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003; 21(20):3814-25. DOI: 10.1200/JCO.2003.11.052. View

16.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L . Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 2011; 21(5):852-8. DOI: 10.1097/IGC.0b013e31821a3726. View

17.

Rein B, Gupta S, Dada R, Safi J, Michener C, Agarwal A . Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011; 2011:475983. PMC: 3090619. DOI: 10.1155/2011/475983. View

18.

Bingle L, Cross S, High A, Wallace W, Rassl D, Yuan G . WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006; 7:61. PMC: 1459147. DOI: 10.1186/1465-9921-7-61. View

19.

Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C . HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011; 412(15-16):1447-53. DOI: 10.1016/j.cca.2011.04.028. View

20.

Fauvet R, Dufournet C, Poncelet C, Uzan C, Hugol D, Darai E . Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J Surg Oncol. 2005; 92(4):337-43. DOI: 10.1002/jso.20424. View